New combo therapy aims to tame stubborn transplant complication
NCT ID NCT06663722
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This study tests whether combining the drug axatilimab with a blood-filtering treatment called ECP can help people with chronic graft-versus-host disease (cGVHD), a condition where donor immune cells attack the recipient's body after a stem cell transplant. About 49 participants aged 12 and older who have not responded to at least two prior treatments will receive the combination. The main goal is to see how many achieve a partial or complete response, while also tracking side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.